SAN DIEGO, Oct. 19, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced, after review of all available safety data, that it will advance to the third cohort of patients in the Phase 1b MAD study of RGSL8429 for the treatment of ADPKD. Patients in the third cohort will receive 3 mg/kg of RGLS8429 or placebo every other week for three months.
Read more at prnewswire.comhello world
Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
